139679-45-1 Usage
General Description
"1-(4-Fluoro-benzoyl)-piperidine-4-carboxylic acid" is a chemical compound with the molecular formula C16H17NO3F. It is a piperidine derivative with a carboxylic acid group and a fluorobenzoyl group attached to the piperidine ring. 1-(4-FLUORO-BENZOYL)-PIPERIDINE-4-CARBOXYLIC ACID is often used as a building block in the synthesis of pharmaceuticals and other organic molecules. It may also have potential applications in medicinal chemistry and drug discovery due to its structural features. Additionally, it may exhibit biological activity and could be of interest to researchers in the field of organic chemistry and drug development.
Check Digit Verification of cas no
The CAS Registry Mumber 139679-45-1 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,3,9,6,7 and 9 respectively; the second part has 2 digits, 4 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 139679-45:
(8*1)+(7*3)+(6*9)+(5*6)+(4*7)+(3*9)+(2*4)+(1*5)=181
181 % 10 = 1
So 139679-45-1 is a valid CAS Registry Number.
InChI:InChI=1/C13H14FNO3/c14-11-3-1-9(2-4-11)12(16)15-7-5-10(6-8-15)13(17)18/h1-4,10H,5-8H2,(H,17,18)
139679-45-1Relevant articles and documents
Exploration of novel piperazine or piperidine constructed non-covalent peptidyl derivatives as proteasome inhibitors
Zhuang, Rangxiao,Gao, Lixin,Lv, Xiaoqing,Xi, Jianjun,Sheng, Li,Zhao, Yanmei,He, Ruoyu,Hu, Xiaobei,Shao, Yidan,Pan, Xuwang,Liu, Shourong,Huang, Weiwei,Zhou, Yubo,Li, Jia,Zhang, Jiankang
, p. 1056 - 1070 (2017)
A series of novel piperazine or piperidine-containing non-covalent peptidyl derivatives possessing a neopentyl-asparagine residue were designed, synthesized and evaluated as proteasome inhibitors. All target compounds were screened for their 20S proteasom
Imidazolylbenzoyl substituted heterocycles
-
, (2008/06/13)
Novel imidazolybenzoyl substituted heterocycles and their use as cardiovascular agents most especially as Class III antiarrhythmic agents is described. Pharmaceutical formulations containing such compounds are also discussed.
